RedHill Biopharma Ltd. (RDHL)

0,4530 -0,0051 (-1,11%) In data: 11:05AM EDT. Mercato aperto.

RedHill Biopharma Ltd.

21 Ha’arba’a Street
Tel Aviv 6473921
Israel
972 3 541 3131
https://www.redhillbio.com

Settore/i: Healthcare
Settore: Drug Manufacturers - Specialty & Generic
Impiegati a tempo pieno: 53

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Dror Ben-Asher	Co-Founder, Chairman & CEO	594,61k	N/D	1966
Mr. Razi Ingber	Chief Financial Officer	339,82k	N/D	1984
Mr. Gilead Raday MPhil, MSc	Chief Operating Officer	365,56k	N/D	1975
Mr. Adi Frish	Chief Corporate & Business Development Officer	339,3k	N/D	1970
Mr. Rick D. Scruggs	Chief Commercial Officer, President of RedHill Biopharma Inc. & Director	469,8k	N/D	1960
Ms. Alexandra Okmian	Senior Business Development & Investor Relations Manager	N/D	N/D	N/D
Dr. Reza Fathi Ph.D.	Senior Vice President of Research & Development	299,29k	N/D	1955
Mr. Guy Goldberg J.D.	Chief Business Officer	338,13k	N/D	1976
Dr. June S. Almenoff FACP, M.D., Ph.D.	Chief Medical Officer	N/D	N/D	1957
Ms. Patricia Anderson B.Sc. RAC	Senior Vice President of Regulatory Affairs	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.

Governance aziendale

L'ISS Governance QualityScore di RedHill Biopharma Ltd. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.